【摘要】 目的:观察帕立骨化醇治疗血液透析患者继发性甲状旁腺功能亢进症（SHPT）的有效性及安全性。方法:选择2016年8月至2016年12月深圳市第二人民医院血液透析中心维持性血液透析伴发SHPT患者12例,全段甲状旁腺素（iPTH）600¹500pg·m L^-1,初始给予帕立骨化醇5μg·次^-1,每周3次治疗,根据血清iPTH及钙磷水平调整剂量。结果:本研究12例患者应用帕立骨化醇治疗3个月后,按照美国肾脏病与透析病人生存质量指导指南透析患者血清iPTH目标范围150³00pg·mL^-1,达标率为25.0%,降幅最高达到79.3%,最低降幅也有26.0%。结论:帕立骨化醇注射液能有效降低血清iPTH水平,治疗SHPT,治疗过程中注意监测血钙血磷水平。更多还原

【Abstract】 Objective To observe the efficacy and safety of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. Methods 12 patients with secondary hyper-parathyroidism, whose whole parathyroid hormone(iPTH) were 600 ~ 1500pg/ml, were selected from the hemodialysis center of Shenzhen second people’s hospital from August 2016 to November 2016. These patients were initially treated with paricalcitol 5μg/time, three times a week,and were adjusted the dosage according to serum iPTH and calcium phosphorus level. Results Following the K/DOQI guide,the target range of dialysis patients was 150 ~ 300pg/ml.In this group, 12 cases were treated with paricalcitol for 3 months,the target rate of serum iPTH was 25%, and the decline ranged from 26% to 79.3%. Conclusion Paricalcitol injection can effectively reduce serum iPTH levels, treat SHPT, and monitor blood calcium phosphorus levels during treatment.更多还原